tiprankstipranks
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
US Market
ALLO
Allogene Therapeutics
RESEARCH TOOLSreports
Want to see ALLO full AI Analyst Report?

Allogene Therapeutics (ALLO) Income Statement

1,759 Followers

Allogene Therapeutics Income Statement

Last quarter (Q4 2025), Allogene Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q4, Allogene Therapeutics's net income was $-38.81M. See Allogene Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 0.00$ 22.00K$ 95.00K$ 156.00K$ 114.09M
Gross Profit
$ -12.36M$ 22.00K$ 95.00K$ -14.14M$ 114.09M
Operating Expenses
$ 194.57M$ 273.22M$ 327.83M$ 321.40M$ 294.28M
Depreciation and Amortization
$ 12.36M$ 13.64M$ 14.20M$ 14.29M$ 10.45M
EBITDA
$ -194.57M$ -243.33M$ -313.07M$ -321.24M$ -169.74M
Operating Income
$ -206.93M$ -273.20M$ -327.74M$ -335.54M$ -180.19M
Other Income/Expenses
$ 16.05M$ 16.05M$ 472.00K$ -4.88M$ -1.86M
Pretax Income
$ -190.89M$ -257.15M$ -327.26M$ -340.41M$ -182.05M
Net Income
$ -190.89M$ -257.59M$ -327.26M$ -340.41M$ -182.05M
Per Share Metrics
Basic EPS
$ -0.87$ -1.32$ -2.09$ -2.38$ -1.34
Diluted EPS
$ -0.87$ -1.32$ -2.09$ -2.38$ -1.34
Weighted Average Shares Outstanding
 220.62M 194.81M 156.93M 143.15M 135.82M
Weighted Average Shares Outstanding (Diluted)
 220.62M 194.81M 156.93M 143.15M 135.82M
Currency in USD

Allogene Therapeutics Earnings and Revenue History